ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P18-18 2018 Renewal Changes Summary For Aware Professional Providers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 01, 2018
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2961 - 2970 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P65-18 Lab Management Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers - eviCore Healthcare Specialty Utilization Management Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P52-18 2019 Minnesota Medicare Network Update
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P56-18 New Medical, Medical Drug and Behavioral Health Policy Management Updates for Commercial Lines of Business - Effective January 7, 2019
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P53R1-18 Minnesota Health Care Programs Policies Effective December 1, 2018
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P34-16 New Drug-Related Prior Authorization Criteria for Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blocker Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 27, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P47-16 New Drug-Related Prior Authorization Requirements for Botulinum Toxin, Remicade, Rituxan and Biologic Immunomodulators
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 10, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P56-17 Implementation of a Medical Drug Exclusions List
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 16, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P5R1-17 Updated: Third Party Payments of Premium and/or Cost-Sharing
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 05, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P50-16 Addition of a Drug (Xiidra) to the Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 28, 2016